ATEA PHARMACEUTICALS INC (AVIR) Stock News
NASDAQ:AVIR - Nasdaq - US04683R1068 - Common Stock - Currency: USD
AVIR Latest News, Press Relases and Analysis
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from...
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
Atea Pharmaceuticals Issues Statement Regarding Director Nominations
No Shareholder Action is Required at this Time...
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company...
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
Enters into Agreement with Bradley L. Radoff and Michael Torok...
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
Enters into Agreement with Bradley L. Radoff and Michael Torok
Mentions: COYA
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV...
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company...
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
Atea Pharmaceuticals Issues Statement Regarding Director Nominations
No Shareholder Action is Required at this Time
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company...
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial
Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing analyst skepticism over its drug.
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV...
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the...
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged...
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the...
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged...
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week Treatment Duration Regimen Was...
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the...
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the...